Agri Investment Fund

Aphea.Bio NV/SA, founded in 2017 and headquartered in Gent, Belgium, specializes in the manufacture of biopesticides and biostimulants aimed at promoting sustainable agriculture. The company focuses on developing next-generation biopesticides derived from natural microorganisms, providing alternatives to traditional chemical pesticides, which face increasing regulatory scrutiny. Additionally, Aphea.Bio creates innovative biostimulants that enhance crop growth by improving nutrient uptake from the soil. Its products are designed to increase crop yields and protect against specific fungal diseases, contributing to more sustainable farming practices.

Aphea.Bio NV/SA, founded in 2017 and headquartered in Gent, Belgium, specializes in the manufacture of biopesticides and biostimulants aimed at promoting sustainable agriculture. The company focuses on developing next-generation biopesticides derived from natural microorganisms, providing alternatives to traditional chemical pesticides, which face increasing regulatory scrutiny. Additionally, Aphea.Bio creates innovative biostimulants that enhance crop growth by improving nutrient uptake from the soil. Its products are designed to increase crop yields and protect against specific fungal diseases, contributing to more sustainable farming practices.

Animab BV, a biotechnology company, develops monoclonal antibodies for livestock. It develops mimic secretory IgA, a type of natural antibody passed through colostrum and milk to protect nursing animals. The company will help swine producers with antibiotics for the control of gastrointestinal pathogens. Animab BV was incorporated in 2020 and is based in Ghent, Belgium.

ViroVet NV develops virus control solutions for the livestock industry. It offers antiviral drugs for the control and treatment of respiratory diseases of cattle and swine. The company also offers modified live virus vaccines for endemic and epizootic viral livestock diseases. ViroVet NV was founded in 2015 and is based in Leuven, Belgium.

Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.

Aphea.Bio NV/SA, founded in 2017 and headquartered in Gent, Belgium, specializes in the manufacture of biopesticides and biostimulants aimed at promoting sustainable agriculture. The company focuses on developing next-generation biopesticides derived from natural microorganisms, providing alternatives to traditional chemical pesticides, which face increasing regulatory scrutiny. Additionally, Aphea.Bio creates innovative biostimulants that enhance crop growth by improving nutrient uptake from the soil. Its products are designed to increase crop yields and protect against specific fungal diseases, contributing to more sustainable farming practices.

Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination of individuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.

Fugeia NV specializes in developing ingredients and nutrition technologies, focusing on arabinoxylan-oligosaccharides (AXOS), which offer various health benefits associated with wholegrain wheat. These benefits include potential prevention of lifestyle diseases such as diabetes, obesity, cardiovascular conditions, and cancer. The company has innovated technologies for prebiotic bread and AXOS-enriched beer, enhancing the levels of these beneficial compounds in these products. Fugeia's offerings cater to a wide range of market segments, including dairy and non-dairy beverages, ready-to-eat cereals, cookies, biscuits, bread, and pastries, as well as dietary supplements and therapeutics. Founded in 2008, the company is based in Heverlee, Belgium.